Last reviewed · How we verify
Maltobiose (MALTOSE)
Maltobiose (generic name: MALTOSE) is a drug. It is currently in Phase 3 development.
Maltobiose works by interacting with specific biological pathways, although the exact mechanism is unknown.
Maltobiose is an oligosaccharide, a type of complex sugar molecule. It is also known by other names, including maltose, which is a synonym for maltobiose.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | MALTOSE |
|---|---|
| Modality | Oligosaccharide |
| Therapeutic area | Other |
| Phase | Phase 3 |
Mechanism of action
Imagine your body's cells are like locks, and maltobiose is a key that fits into those locks. When it binds to the locks, it can trigger a response that helps to treat certain conditions. However, the exact way it works is still a mystery and requires further research.
Approved indications
Common side effects
- Appendicolith
- Blood phosphorus increased
- Appendicitis
- Ventricular fibrillation
- Cardiogenic shock
- Ascites
- Stress
- Multiple organ dysfunction syndrome
Key clinical trials
- V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency (PHASE3)
- Comparison of Oral vs Intravenous Iron Therapy for the Treatment of Postpartum Anemia (NA)
- Efficacy Test of Curcuminoid Standardized Turmeric Capsules to Improving Inflammatory Biomarkers in Osteoarthritis Genu (PHASE2,PHASE3)
- Efficacy of Ferric Carboxymaltose Versus Iron Sucrose in Non-dialysis Dependent Chronic Kidney Disease Patients (NA)
- Effect of Acupuncture and Herbal Medicine on Bowel Recovery After Abdominal Surgery (NA)
- Transdermal Microneedle Lignocaine Delivery Versus EMLA Patch for Topical Analgesia Before Venepuncture Procedure To Adults in Clinical Setting (PHASE1,PHASE2)
- Maternal Probiotic Intervention to Improve Gut Health (PHASE2)
- Probiotic Administration for Adolescent Depression (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Maltobiose CI brief — competitive landscape report
- Maltobiose updates RSS · CI watch RSS
Frequently asked questions about Maltobiose
What is Maltobiose?
How does Maltobiose work?
What is the generic name of Maltobiose?
What development phase is Maltobiose in?
What are the side effects of Maltobiose?
Related
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing